As of Jul 29
| -0.17 / -0.33%|
The 17 analysts offering 12-month price forecasts for Novozymes A/S have a median target of 51.25, with a high estimate of 59.36 and a low estimate of 41.31. The median estimate represents a -0.85% decrease from the last price of 51.69.
The current consensus among 17 polled investment analysts is to Buy stock in Novozymes A/S. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.